Dr. Howard Smith Oncall

Vidcast:  https://www.instagram.com/p/DBuFOozsd4X/ Taking semaglutide, marketed as Ozempic, Rybelsus, and Wegovy, reduced the risk of developing Alzheimer’s Disease by 40 up to 70 percent, compared with other medications.  This the finding of a large retrospective case study of over 1 million type 2 diabetics by Cleveland’s Case Western University  and published in the Alzheimer’s Association journal. The researchers compared the incidence of a first time diagnosis of Alzheimer’s in those diabetics taking semaglutide versus those taking insulin or other diabetic medications.  Semaglutide reduced the risk of this dementia by 67% compared with insulin and even a more moderate 41% compared with other GLP-1 receptor agonists but not the newest tirazepatide.  This benefit was true for type 2 diabetics with or without a diagnosis of obesity. This observation, if confirmed with prospective randomized studies, could add Alzheimer’s Disease prevention to the list of benefits for the GLP-1 receptor agonists which a